Skip to the beginning of the images gallery

Add to Wish List

Toripalimab Biosimilar - Research Grade

In stock

Only %1 left

SKU

ICH5002

Add to Compare

Be the first to review this product

$315.00 - $19,890.00

Toripalimab Biosimilar - Research Grade

Endotoxin

<1EU/mg Determined by LAL gel clotting assay

Purity

>95% by SDS-PAGE and HPLC

Species Reactivity

Human

Target

PD-1

Concentration

>1mg/ml

Isotype

Human IgG4

Host

Humanized

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q15116

Gene Id

5133

Rrid

RRID:AB_2921553

Shipping Conditions

Blue ice

Background

This product is an unconjugated, non-therapeutic recombinant analog of toripalimab, a humanized anti-PD-1 monoclonal antibody, supplied strictly for research use. Built around the same target as the originator drug (human PD-1 / PDCD1), it is intended as a bench reagent for characterising PD-1 biology and the PD-1/PD-L1 checkpoint axis, not as a clinical or veterinary product. Typical research applications include use as a binding and blocking reference standard, a positive control in PD-1 detection and receptor-occupancy assays, a benchmarking tool alongside other checkpoint-directed antibodies, and a building block for ADCC or antibody-drug-conjugate development workflows. It is offered at low endotoxin (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg) and in bulk milligram-to-gram quantities to support in-vitro assay development, preclinical cell-based studies, and formulation or method optimisation. Because it is a research-grade analog rather than the licensed therapeutic, it should be validated in the user's own system before use. No clone or proprietary sequence is implied; the reagent is defined by its target and function. PD-1 (programmed cell death protein 1; gene PDCD1; UniProt Q15116) is a type I transmembrane immune checkpoint receptor of the CD28/immunoglobulin superfamily, expressed on activated T cells, B cells, NK cells, and myeloid subsets. Its cytoplasmic tail carries ITIM and ITSM motifs that recruit the phosphatase SHP-2 upon ligand engagement, dampening TCR and CD28 signalling. PD-1 binds two ligands, PD-L1 (CD274) and PD-L2 (PDCD1LG2), which are upregulated in inflamed and tumour tissue. Sustained PD-1 signalling drives T-cell exhaustion and peripheral tolerance, and tumours exploit this axis to evade immune attack. Blocking the PD-1/PD-L1 interaction restores effector T-cell function, the mechanistic basis for checkpoint-inhibitor immunotherapy.

Other Names

Programmed cell death protein 1, Pdcd1, CD279

Specificity

Detects human PD-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Toripalimab.

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Formulation

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Storage

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Suggested H1

Toripalimab (anti-PD-1) Biosimilar

Faq (q&a)

Q: Is the Toripalimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Toripalimab suitable for in vivo studies?